1-3 of 3
Harveen Dhillon Natarajan
Close
Sort by
Journal Articles

Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia

Vera Hoving, Albertine Donker, Enrikas Vainorius, Harveen Dhillon Natarajan, Jenn Lachey, Simon Cooper, Dorine W. Swinkels, Saskia Schols
Journal: Blood
Blood (2022) 140 (Supplement 1): 2475–2476.
https://doi.org/10.1182/blood-2022-163698
Published: 2022
Journal Articles

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Lynette C.Y. Chee, David M Ross, Shuh Ying Tan, Joel Wight, George Kannourakis, Miranda Ross, Wei Feng, Ying Jiang, Harveen Dhillon Natarajan, Christine Graham, Christopher Rovaldi, Simon Cooper, Jen L. Salstrom
Journal: Blood
Blood (2022) 140 (Supplement 1): 8181–8183.
https://doi.org/10.1182/blood-2022-166578
Published: 2022
Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

David M Ross, Alejandro Arbelaez, Lynette C.Y. Chee, Chun Yew Fong, Devendra Hiwase, George Kannourakis, John Kwan, James Liang, Anish Puliyayil, Hannah Rose, Shuhying Tan, Tse-Chieh Teh, David Alan Westerman, Joel Wight, Chris Rovaldi, Elissa M. Furutani, Adrienne Gaggi, Ying Jiang, Jenn Lachey, Harveen Dhillon Natarajan, Claudia Ordonez
Journal: Blood
Blood (2021) 138 (Supplement 1): 3675.
https://doi.org/10.1182/blood-2021-147335
Published: 2021